STOCKHOLM | Jotup

Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes

Retrieved on:

Donnerstag, März 14, 2024

Diabetes, Health, Obesity, Disease, Patient, DSM-IV codes, CRS, Quality of life, Clinical trial, Safety, CSO, Ageing, Pharmaceutical industry

This clinical trial, conducted on both healthy volunteers and individuals with T2D, underscores the safety of ATR-258 as a novel β2-adrenoceptor agonist, offering a revolutionary approach to type 2 diabetes treatment.

Key Points:

This clinical trial, conducted on both healthy volunteers and individuals with T2D, underscores the safety of ATR-258 as a novel β2-adrenoceptor agonist, offering a revolutionary approach to type 2 diabetes treatment.
The unique mechanism of action of ATR-258 enables the selective modulation of specific positive intracellular signaling pathways.
It underscores the therapeutic value of this novel pathway for the treatment of type 2 diabetes.
The final data demonstrated that ATR-258 was safe and well tolerated in healthy volunteers, and, importantly, also in the T2D patients.

Hexagon publishes the Annual Report and Sustainability Report 2023

Retrieved on:

Mittwoch, März 27, 2024

Sustainability, Hexagon AB, Annual general meeting, Hexagon, Annual report

STOCKHOLM, March 27, 2024 /PRNewswire/ -- Hexagon's Annual Report and Sustainability Report 2023 is now available at Hexagon's website hexagon.com .

Key Points:

STOCKHOLM, March 27, 2024 /PRNewswire/ -- Hexagon's Annual Report and Sustainability Report 2023 is now available at Hexagon's website hexagon.com .
Hexagon intends to solely distribute the reports digitally.
If you however still want to receive a printed copy of the Annual Report, please contact Hexagon at [email protected] or call +46 (0)8 601 26 20.
Anton Heikenström, Investor Relations Manager, Hexagon AB, +46 8 601 26 26, [email protected]
This information is information that Hexagon AB (publ) is obliged to make public pursuant to the Securities Markets Act.

NOTICE TO THE ANNUAL GENERAL MEETING IN HEXAGON AB (publ)

Retrieved on:

Donnerstag, März 21, 2024

STOCKHOLM, March 21, 2024 /PRNewswire/ -- The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen) and the company's Articles of Association, decided that shareholders shall be able to exercise their voting rights by postal voting before the General Meeting. Consequently, shareholders may choose to exercise their voting rights at the AGM by attending in person, through a proxy or by postal voting.

Key Points:

Notice of attendance to the Annual General Meeting can be given on Hexagon's website, www.hexagon.com , or by post to: Hexagon AB, "Annual General Meeting", c/o Euroclear Sweden AB, P.O.
Completed and signed postal voting forms can be sent by mail to Hexagon AB, "Annual General Meeting", c/o Euroclear Sweden AB, P.O.
The Nomination Committee elected in anticipation of the 2024 Annual General Meeting, comprising Mikael Ekdahl (Melker Schörling AB), Jan Dworsky (Swedbank Robur fonder), Brett Watson (Infor) and Daniel Kristiansson (Alecta) has proposed that Ola Rollén be elected Chairman of the 2024 Annual General Meeting.
If the Annual General Meeting so resolves, the dividend is expected to be distributed by Euroclear Sweden AB starting on Friday 10 May 2024.

Celebian Launches Innovative Subscription Service for TikTok Likes and Views

Retrieved on:

Montag, Februar 12, 2024

Social media, Automatic, Subscription business model, Creativity, Business model, Partnership, Mobile phone

Stockholm, Sweden--(Newsfile Corp. - February 12, 2024) - Celebian has officially unveiled its latest offering: a cutting-edge subscription service dedicated to providing TikTok users with automatic likes and views.

Key Points:

Stockholm, Sweden--(Newsfile Corp. - February 12, 2024) - Celebian has officially unveiled its latest offering: a cutting-edge subscription service dedicated to providing TikTok users with automatic likes and views.
With the digital space becoming increasingly competitive, Celebian recognizes the importance of standing out on popular platforms like TikTok.
The service is available through two distinct but equally valuable offerings: Automatic TikTok Likes and the Automatic TikTok Views subscriptions.
For more information about Celebian's TikTok likes and views subscription service, visit the website .

ASM Global Secures Major Naming Rights Deal for Sweden’s National Soccer Stadium to Be Known as Strawberry Arena

Retrieved on:

Montag, Januar 15, 2024

ASM Global today announced a new naming rights partnership with Strawberry Hotel Group beginning in July which will rename the former Friends Arena in Stockholm – a mainstay of major live entertainment experiences – to Strawberry Arena.

Key Points:

ASM Global today announced a new naming rights partnership with Strawberry Hotel Group beginning in July which will rename the former Friends Arena in Stockholm – a mainstay of major live entertainment experiences – to Strawberry Arena.
Venue operator ASM Global and new naming rights partner Strawberry – which has over 240 hotels in the region – plan to increase the already market-leading live entertainment experiences to guests, fans, members, customers and artists alike.
Petter Stordalen, owner, and founder of Strawberry, said, "The new name, Strawberry Arena, symbolizes experience and diversity, setting the arena as a place for energy, courage and enthusiasm.
"In July, the arena will change its name to Strawberry Arena, and this is a major milestone for our group and our history in Sweden.

Mines of Dalarnia Terraformed Update Now Available on Mainnet

Retrieved on:

Freitag, November 17, 2023

Gems, Golden, Mining, DAR, Capsule, Logic, AskMe, Miner, Social media, Mine, Terraforming, Project, Video game

Stockholm, Sweden--(Newsfile Corp. - November 17, 2023) - Mines of Dalarnia, an action-adventure blockchain-based gaming platform, proudly announces its highly anticipated Terraformed update.

Key Points:

Stockholm, Sweden--(Newsfile Corp. - November 17, 2023) - Mines of Dalarnia, an action-adventure blockchain-based gaming platform, proudly announces its highly anticipated Terraformed update.
Mines of Dalarnia Terraformed Update is now available for download.
The recordings are available on Mines of Dalarnia official YouTube channel: New Economy Design Part 1 and New Economy Design Part 2 .
As Mines of Dalarnia continues to evolve, to offer more engaging and enriching experiences for its players, the team welcomes feedback and welcomes every action-adventure gamer to join the Mines of Dalarnia community.

Vironova BioAnalytics AB Acquired by an investor syndicate, led by Quatre Lab, to expand its TEM services for the pharmaceutical industry; to be rebranded as QuTEM

Retrieved on:

Montag, November 20, 2023

Partnership, Pharmacy, Acquisition, Good manufacturing practice, TEM, Quality control, GMP, Growth, Network equipment provider

This strategic move will enable Vironova BioAnalytics to enhance its capabilities and continue to deliver TEM analyses according to Good Manufacturing Practices (GMP) for the pharmaceutical industry.

Key Points:

This strategic move will enable Vironova BioAnalytics to enhance its capabilities and continue to deliver TEM analyses according to Good Manufacturing Practices (GMP) for the pharmaceutical industry.
Following the completion of the acquisition, the company will be renamed and rebranded as QuTEM.
Vironova BioAnalytics has established a strong reputation as a trusted partner for pharmaceutical companies globally, known for its commitment to high-quality standards.
For more information about QuTEM (formerly Vironova BioAnalytics) and its TEM services, please visit qutem.com.

Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration

Retrieved on:

Dienstag, Oktober 10, 2023

Membrane, Partnership, Knowledge, SLC, CSO, Therapy, Drug discovery, G protein-coupled receptor, Research, Fine chemical, Pharmaceutical industry, Vaccine, Boron group

The partnership between Salipro Biotech and Icosagen will build on Salipro's track record of establishing multiple collaboration and licensing agreements with leading pharma and biotech companies to enable drug discovery against complex membrane protein targets, ranging from small molecule drug discovery programs to structural biology and antibody discovery.

Key Points:

The partnership between Salipro Biotech and Icosagen will build on Salipro's track record of establishing multiple collaboration and licensing agreements with leading pharma and biotech companies to enable drug discovery against complex membrane protein targets, ranging from small molecule drug discovery programs to structural biology and antibody discovery.
We are excited to unlock the potential of these targets with Icosagen and develop novel drugs that can improve patient outcomes," said Jens Frauenfeld, CEO of Salipro Biotech.
Their knowledge in antibody discovery, encompassing high-throughput antibody screening and variety of lead optimization techniques will enrich the collaboration and form solid basis for supporting biologic drug developments in the future.
Both teams in Icosagen and Salipro Biotech are always finding ways to push the boundaries in novel technologies of biologics development.

Eureka Partners Fortifies Its Stance in Blockchain and Cryptocurrency with $40 Million Investment from Nordic Venture Innovations AB

Retrieved on:

Montag, September 25, 2023

Blockchain, Growth, Ecosystem, Partnership, Corporate venture capital, Web3, Partner, Empowerment, Marketing, Internet, Cryptocurrency, Nordic

This strategic investment represents a significant milestone in Eureka Partners' journey and will expedite its growth within the blockchain and cryptocurrency domains, providing additional resources and support for future innovation and ecosystem development.

Key Points:

This strategic investment represents a significant milestone in Eureka Partners' journey and will expedite its growth within the blockchain and cryptocurrency domains, providing additional resources and support for future innovation and ecosystem development.
Eureka Partners distinguishes itself with a youthful and dynamic team, a group of individuals primed to adapt swiftly to the rapidly evolving crypto landscape.
Proudly, the team at Eureka Partners consists of true crypto natives-individuals who have been deeply immersed in the blockchain and cryptocurrency space since its inception.
This substantial investment from Nordic Venture Innovations AB is a resounding vote of confidence in Eureka Partners' vision and capabilities.

Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program

Retrieved on:

Dienstag, September 12, 2023

Drug discovery, Membrane, Sumitomo Group, Senior, Eurosport 1, G protein-coupled receptor, CNS, Sumitomo Pharma, Pharmaceutical industry

STOCKHOLM, Sweden, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Sumitomo Pharma Co., Ltd. to reveal the mechanism of action and pharmacological characterization of a drug candidate.

Key Points:

The collaboration leverages Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target to investigate the pharmacological characteristics of a compound from Sumitomo Pharma’s discovery program.
STOCKHOLM, Sweden, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Sumitomo Pharma Co., Ltd. to reveal the mechanism of action and pharmacological characterization of a drug candidate.
Under the terms of the collaboration, Salipro Biotech will utilize its unique expertise in stabilizing challenging membrane proteins such as GPCRs, ion channels and transporters via its proprietary Salipro® technology platform to advance a Sumitomo Pharma’s drug discovery program by characterizing a drug candidate with the desired therapeutic properties against a selected target.
“We are excited to be working with Sumitomo Pharma to investigate this drug candidate and its mechanism of action,” said Jens Frauenfeld, CEO of Salipro Biotech.